Clinical implications of aberrant TSG101 transcripts in acute myeloblastic leukemia

Leukemia and Lymphoma

Volumn 36, Issue 5-6, 2000, Pages 463-466

  Lin, Sheng Fung ^a   Lin, Pai Mei ^a   Liu, Ta Chih ^b   Chang, Jan Gowth ^a   Sue, Yu Chieh ^a   Chen, Tyen Po ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Aberrant transcripts; Acute myeloid leukemia; Clinical implication; TSG101

Indexed keywords

LACTATE DEHYDROGENASE;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL CYCLE; CELL STRAIN 3T3; CELL TRANSFORMATION; CHROMOSOME 11P; CONTROLLED STUDY; GENE DELETION; GENETIC STABILITY; HEMATOPOIETIC CELL; HOMOZYGOSITY; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; METASTASIS; MOUSE; MULTIVARIATE ANALYSIS; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; REMISSION; RNA SPLICING; SEQUENCE HOMOLOGY; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

EID: 0033957126     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009148393     Document Type: Short Survey

References (25)

1. Fearon, E. R. and Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis. Cell, 61, 759-769.
2. Bishop, J. M. (1995) Cancer: the rise of the genetic paradigm. Genes Dev, 9, 1309-1315.
3. Ku, W. H., Liu, I. L., Yen, M. S., Chang-Chien, C. C., Yue, C. T., Ma, Y. Y., Chang, S. F., Ng, H. T., Wu, C. W. and Shen, C. Y. (1997) Genomic deletion and p53 inactivation in cervical carcinoma. Int J Cancer, 17, 270-276.
4. Takita, J., Hayashi, Y. and Yokota, J. (1997) Loss of heterozygosity in neuroblastomas - an overview. Eur J Cancer, 33, 1971-1973.
5. Drach, J., Ackermann, J., Fritz, E., Kromer, E., Schuster, R., Gisslinger, H., DeSantis, M., Zojer, N., Fiegel, M., Roka, S., Schuster, J., Heinz, R., Ludwig, H. and Huber, H. (1998) Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional - dose chemotherapy. Blood, 92, 802-809.
6. Li, L. and Cohen, S. N. (1996) Tsg101 : a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell, 85, 319-329.
7. Li, L., Li, X., Francke, U. and Cohen, S. N. (1997) The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell, 88, 143-154.
8. Lee, M. P. and Feinberg, A. P. (1997) Aberrant splicing but not mutations of TSG101 in human breast cancer. Cancer Res, 57, 3131-3134.
9. Lin, S. Y., Chen, Y. J. and Chang, J. G. (1998) Multiple truncated transcripts of TSG101 in gastrointestinal cancers. J Gastroenterol Hepatol, 13, 1111-1113.
10. Maucuer, A., Camonis, J. H. and Sobel, A. (1995) Stathmin interaction with a putative kinase and coiled coil-forming protein domains. Proc Natl Acad Sci USA, 92, 99-108.
11. Koonin, E. V. and Abagyan, R. A. (1997) TSG101 may be the prototype of a class of dominant negative ubiquitin regulators. Nat Genet, 16, 330-331.
12. Ponting, C. P., Cai, Y. D. and Bork, P. (1997) The breast cancer gene product TSG101: a regulator of ubiquitination? J Mol Med, 75, 467-469.
13. Zhong, Q., Chen, C. F., Chen, Y., Chen, P. L. and Lee, W. H. (1997) Identification of cellular TSG101 protein in multiple human breast cancer cell lines. Cancer Res, 57, 4225-4228.
14. Xie, W., Li, L. and Cohen, S. N. (1998) Cell cycle-dependent subcellular localization of the TSG101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency. Proc Natl Acad Sci USA, 95, 1595-1600.
15. Wagner, K. U., Dierisseau, P., Rucker, E. B. 3rd, Robinson, G. W. and Hennighausen, L. (1998) Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants. Oncogene, 17, 2761-2770.
16. Ferrer, M., Lopez-Borges, S. and Lazo, P.A. (1999) Expression of a new isoform of the tumor susceptibility TSG101 protein lacking a leucine zipper domain in Burkitt lymphoma cell lines. Oncogene, 18, 2253-2259.
17. Ali, I. U., Lidereau, R., Theillet, C. and Callahan, R. (1987) Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Science, 238, 185-188.
18. Reeve, A. E., Sih, S.A., Raizis, A. M. and Feinberg, A. P. (1989) Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumor cells. Mol Cel. Biol, 9, 1799-1803.
19. Steiner, P., Barnes, D. M., Harris, W. H. and Weinberg, R. A. (1997) Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancer. Nat Gen, 16, 332-333.
20. Gayther, S. A., Barski, P., Batley, S. J., Li, L., de Foy, K. A., Cohen, S. N., Ponder, B. A. and Caldas, C. (1997) Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Oncogene, 15, 2119-2126.
21. Sun, Z., Pan, J., Bubley, G. and Balk, S. P. (1997) Frequent abnormalities of TSG101 transcripts in human prostate cancer. Oncogene, 15, 3121-3125.
22. Lin, P. M., Liu, T. C., Chang, J. G., Chen, T. P. and Lin, S. F. (1998) Aberrant TSG101 transcripts in acute myeloid leukaemia. Br J Haematol, 102, 753-758.
23. Hampl, M., Hampl, J., Plachke, J., Fitze, G., Schackert, G., Saeger, H. D. and Schackert, H. K. (1998) Evidence that TSG101 aberrant transcripts are PCR artifacts. Bioche Biophys Res Commun, 248, 753-760.
24. Wang, N. M. and Chang, J. G. (1999) Are aberrant transcripts of FHIT, TSG101, and PTEN/MMAC1 oncogenesis related? Int J Mol Med, 3, 491-495.
25. Wagner, K.U., Dierisseau, P. Rucker, E. B. 3rd, Robinson, G.W. and Hennighausen, L. (1998) Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants. Oncogene, 17, 2761-2770.